Etrolizumab

Etrolizumab is a monoclonal antibody designed for the treatment of Ulcerative colitis and Crohn's disease. It is developed by Genentech, a member of the Roche Group.

Mechanism of Action

Etrolizumab is a humanized monoclonal antibody that selectively binds to the beta7 subunit of the integrin heterodimer. This binding inhibits the interaction of the beta7 subunit with MAdCAM-1 and E-cadherin, thereby preventing the migration of leukocytes into gut tissues.

Clinical Trials

Etrolizumab has been studied in Phase III clinical trials for the treatment of moderate to severe ulcerative colitis and Crohn's disease. The results of these trials are pending.

Side Effects

The most common side effects of etrolizumab include nausea, headache, fatigue, and abdominal pain. Serious side effects can include infections, infusion reactions, and liver problems.

See Also

• Monoclonal antibodies
• Ulcerative colitis
• Crohn's disease
• Genentech
• Roche Group